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Abstract
Background Vaniprevir (MK-7009) is a hepatitis C virus
(HCV) non-structural 3/4a protease inhibitor which sig-
nificantly increases virologic response rates in HCV
genotype (GT) 1-infected patients when added to pegin-
terferon and ribavirin (PR).
Methods This was a phase II, multicenter, double-blind,
randomized, dose-ranging study in Japanese patients with
HCV GT1 infection and previous relapse. Patients received
twice daily vaniprevir 100, 300, or 600 mg, or placebo plus
PR for 4 weeks then PR alone for 2 weeks. Further treat-
ment with PR was continued up to a maximum of
72 weeks. The primary endpoint was rapid virologic
response (RVR; undetectable HCV RNA at treatment week
4).
Results Ninety patients completed 4 weeks of vaniprevir/
placebo plus PR. Rates of RVR were significantly higher
with vaniprevir compared with placebo (86, 95, and 76 %
in the vaniprevir 100-, 300-, and 600-mg arms versus 20 %
with control; p\0.001 for all comparisons). Rates of SVR,
an exploratory analysis, in the vaniprevir 100-, 300-,
600-mg, and control arms were 95, 100, 100, and 72 %,
respectively. No patient had virologic breakthrough or non-
response while receiving vaniprevir. There were no serious
adverse events (AEs) or discontinuations due to an AE
during vaniprevir treatment. Diarrhea and nausea were
more common with vaniprevir 600 mg than control or
lower vaniprevir doses.
Conclusion The addition of vaniprevir to PR was asso-
ciated with an increase in RVR and SVR. Combined with a
generally safe and well-tolerated profile, these data sup-
ported the further evaluation of vaniprevir in Japanese
patients with HCV GT1 infection (#NCT00880763).
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Introduction
There are approximately 2 million patients with the hepa-
titis C virus (HCV) infection in Japan [1]. HCV infection is
the leading cause of hepatocellular carcinoma in Japan,
causing more than 30,000 deaths each year. Peginterferon
plus ribavirin dual therapy remains the cornerstone of
treatment for HCV infection, although the direct-acting
antiviral agents, telaprevir and simeprevir, are also avail-
able in Japan for use as part of triple therapy regimens for
selected patients [2]. Triple therapy with telaprevir, pe-
ginterferon alfa-2b, and ribavirin has shown improved
response rate with room for further improvement, but
adverse events (AEs) also increased, including severe
anemia and serious skin rashes [2]. Triple therapy with
simeprevir, peginterferon, and ribavirin has also recently
become available for clinical use in Japan, further
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improving treatment options for patients with HCV infec-
tion in Japan [3]. Additional targeted therapies for the
treatment of HCV infection are being developed with the
aim of further decreasing HCV-related morbidity and
mortality among Japanese patients.
Vaniprevir (MK-7009) is a macrocyclic inhibitor of the
HCV non-structural (NS) 3/4a protease [4]. It exhibits
potent inhibitory activity in in vitro models of HCV rep-
lication and induces a rapid decline in viral load in animal
models of HCV infection [5, 6]. In a phase Ib mono-
therapy study in patients with chronic genotype (GT)1
HCV infection, vaniprevir demonstrated potent antiviral
activity, good plasma exposure, and was generally well
tolerated [7]. In two phase II clinical trials conducted in
non-Japanese patients, addition of vaniprevir to peginter-
feron alfa-2a and ribavirin significantly improved on-
treatment virologic response and sustained virologic
response (SVR) in patients with HCV GT1 infection who
were either naive to previous therapy or had failed pre-
vious treatment with peginterferon and ribavirin [8–10]. In
1 of 2 studies, vaniprevir was administered with pegin-
terferon alfa-2a and ribavirin for 24 or 48 weeks [9, 10].
Alternatively, Manns and colleagues reported the use of
vaniprevir (300 or 600 mg twice daily [bid], or 600 or
800 mg once daily [qd]) plus peginterferon alfa-2a and
ribavirin for 4 weeks followed by open-label peginterferon
alfa-2a and ribavirin for an additional 44 weeks in treat-
ment-naive patients with chronic hepatitis C [8]. In this
latter study, the rate of rapid virologic response (RVR;
undetectable HCV RNA at treatment week 4), the primary
endpoint of the study, was significantly higher in patients
receiving vaniprevir than in those receiving placebo. Data
from this study suggest that vaniprevir is a potent HCV
protease inhibitor with a predictable resistance profile and
favorable safety profile that is suitable for once a day or
twice a day administration [8].
The aim of the present dose-ranging study was to
assess the efficacy and safety of several doses of vani-
previr in combination with peginterferon alfa-2a and
ribavirin in Japanese patients with HCV GT1 infection
who had relapsed following previous treatment with
peginterferon and ribavirin dual therapy to determine the
clinical dose of vaniprevir appropriate for use in Japa-
nese patients for further evaluation of vaniprevir in phase
III studies.
Methods
The study was conducted in accordance with principles of
Good Clinical Practice, approved by the appropriate insti-
tutional review boards and regulatory agencies, and is
registered with ClinicalTrials.gov (#NCT00880763).
Patients
Japanese patients with HCV infection and relapse follow-
ing previous treatment with peginterferon and ribavirin
dual therapy were enrolled. Key inclusion and exclusion
criteria included: age 20–64 years; chronic, compensated,
GT1 HCV infection; and HCV RNA levels C5.0 log IU/
mL at screening. Patients with cirrhosis were excluded: all
patients were required to have fibrosis scores of F0–F2
within 3 years of screening, or F3 within 1 year of
screening. Patients with retinopathy, including retinal
hemorrhage, at screening were also excluded. All patients
were required to meet protocol-defined laboratory criteria
within 75 days prior to first dose.
Study design
This was a phase II, multicenter, double-blind, randomized,
placebo-controlled, and dose-ranging study. Patients were
randomized to receive vaniprevir 100, 300, 600 mg bid, or
matched placebo in combination with peginterferon alfa-2a
(180 lg/week) and ribavirin (600–1,000 mg/day, accord-
ing to body weight) per product label for an initial 4 week
treatment period, and thereafter they received peginterfer-
on alfa-2a plus ribavirin alone for 2 additional weeks. The
initial 4 week treatment period with vaniprevir and pe-
ginterferon alfa-2a plus ribavirin was used to align with the
primary efficacy endpoint of RVR (the proportion of
patients with undetectable HCV RNA at treatment week 4).
The additional 2 weeks of treatment with peginterferon
alfa-2a and ribavirin after the completion of vaniprevir
dosing was implemented to enable continued monitoring of
vaniprevir safety after the completion of triple therapy and
to facilitate uninterrupted continued treatment with pegin-
terferon and ribavirin, in line with current treatment rec-
ommendations [2]. Further treatment with peginterferon
alfa-2a plus ribavirin was then administered at the discre-
tion of each investigator, up to a maximum total treatment
duration of 72 weeks, while also taking into consideration
recommendations from Japanese treatment guidelines.
Treatment blinding was achieved through the centralized
preparation of identical capsules. Dose reduction and
interruption of peginterferon alfa-2a and ribavirin were
permitted in accordance with product labels.
Within the total treatment population, a pharmacokinetic
(PK) cohort was identified to provide blood samples for PK
analyses. Specific sites with the ability to perform an
intensive PK sampling scheme were identified, and patients
screened at these sites were offered the option to participate
in the intensive PK cohort. The computer-generated ran-
domized allocation schedule was prepared by the study
sponsor, independent of the study team, and implemented
by a third-party vendor. Randomization was stratified
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according to participation in the PK cohort with the aim of
enrolling 4–8 patients in the PK cohort per treatment arm.
Endpoints
The study consisted of 2 parts, an initial 6 week phase
(4 weeks of treatment with vaniprevir/placebo plus PR and
a subsequent 2 week post-vaniprevir treatment follow-up
period) followed by a second treatment phase up to
72 weeks in total duration. Primary efficacy and safety
assessments were evaluated based on the treatment period
from baseline to treatment week 6. HCV RNA measure-
ments, evaluation of viral resistance, and assessments of
serious adverse events were based on the entire study
period including treatment period and follow-up period.
The primary efficacy endpoint was RVR, defined as the
proportion of patients with undetectable HCV RNA at
treatment week 4. Secondary virologic endpoints included
the proportion of patients achieving a C2-log10 decrease
and a C3-log10 decrease in viral load from baseline to week
4, and the mean log10 decrease in viral load from baseline
to week 4. Analysis of SVR, defined as the proportion of
patients with undetectable HCV RNA 24 weeks after
completion of treatment, was not defined in the protocol;
however, this endpoint was also calculated in an explor-
atory manner. Patients in the per protocol population for
the primary analysis with an HCV RNA measurement at
each time point were included in the exploratory SVR
analysis.
Resistance-associated variants were to be analyzed at
baseline for all patients, and at virologic failure in patients
with breakthrough viremia or those with a null response
while receiving vaniprevir/placebo through week 4.
Breakthrough viremia was defined as a [1-log10 increase
from nadir HCV RNA at 2 consecutive HCV RNA mea-
surements, or HCV RNA [100 IU/mL at 2 consecutive
visits after becoming undetectable. Null response was
defined as B1-log decrease in HCV RNA through week 4.
The persistence of resistance variants in patients who had
taken vaniprevir was also assessed.
Pharmacokinetic analyses were also performed to eval-
uate the following vaniprevir parameters: area under the
plasma concentration versus time curve from the time of
dosing to 12 h post-dose (AUC0–12 h), maximum plasma
drug concentration (Cmax), trough plasma drug concentra-
tion(Ctrough; i.e., concentration at approximately 12 h post-
dose), time to reach Cmax (Tmax), and apparent terminal
half-life (t). For PK analyses, blood sampling points were
set at pre-dosing on day 1, week 1, and week 4, and any-
time during the visits at weeks 5 and 6 in the all subjects
population. In addition, blood samples for PK analyses
were taken at 0.5, 1, 1.5, 2, 3, 4, 8, and 12 h post-dose on
day 1 and week 4, and at 24 h post-dose on week 4 in the
PK cohort. At each time point, 4 mL blood was placed into
a vacuumized blood collection tube with EDTA-2 K, and
plasma was immediately obtained by centrifugation at
0–10 C and 1,200 relative centrifugal force (9 g) for
15 min.
Safety evaluations included AEs, laboratory values,
physical examinations, 12-lead electrocardiogram, and
vital sign assessments.
Assays
Serum HCV RNA concentrations
Serum HCV RNA levels were measured using Roche
COBAS TaqMan HCV Auto assay. The limit of quan-
tification (LoQ) was 1.2 log IU/mL (15 IU/mL) and the
limit of detection (LoD) was \1.2 log IU/mL, but with no
specific value.
Vaniprevir plasma concentrations
Plasma samples underwent liquid–liquid extraction with
methyl t-butyl ether in a 96-well format. The organic
supernatant was subsequently evaporated under a nitrogen
stream at approximately 40 C, and the remaining residue
was reconstituted in 200 lL 50:50 acetonitrile/water, v/v.
The resulting samples were assessed using a validated
liquid chromatography/tandem mass spectrometry assay
with positive ion electrospray (range 1–1,000 ng/mL).
Pharmacokinetic analyses of vaniprevir plasma concentra-
tions were performed using WinNonlin (Certara, ver.
5.2.1).
Resistance testing
Blood samples were obtained for analysis of vaniprevir
resistance-associated variants at baseline for all patients
and at virologic failure in patients with breakthrough
viremia or those with a null response while receiving
vaniprevir through week 4. Samples were also collected
after completion of vaniprevir treatment to assess the per-
sistence of NS3/4A resistance mutations in patients who
have taken vaniprevir. Viral resistance testing utilized
population sequence analysis of the HCV NS3/4A
region. Due to the sensitivity of this assay, resistance
analysis was performed only on samples with HCV RNA
[1,000 IU/mL.
Statistics
Target randomization was approximately 80 patients in this
study. With evaluable data expected from approximately
18 patients in each treatment arm, this study had 91 %
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power to declare that vaniprevir is superior to placebo,
assuming true RVR rates of 60 % in the vaniprevir plus
PR, and 10 % in the placebo plus PR at week 4.
Primary efficacy analyses were based on the per protocol
population which excluded patients with important deviations
from the protocol that might have substantially affected the
results of the primary efficacy analysis. For the primary end-
point, between treatment arm differences were assessed using
95 % confidence intervals (95 % CI) and associated p-values
calculated using the Miettinen and Nurminen method [11]. A
closed testing procedure with a fixed sequence of tests was
used to adjust for multiplicity of multiple dose levels. For the
secondary efficacy endpoints, 95 % CIs of between treatment
arm differences were calculated using the Miettinen and Nu-
rminen method [11]. A longitudinal data analysis model pro-
posed by Liang and Zeger [12] was used to compare vaniprevir
with placebo with respect to the mean log10 decrease in viral
load. Missing data were excluded from analysis for each time
point. SVR was also summarized in an exploratory manner.
Summary statistics (geometric mean and 95 % CI) for
PK parameters were presented by treatment arm and by day.
Median (range) was also provided for Tmax, and harmonic
mean (pseudo standard deviation) was also provided for t.
Safety analysis was based on the all patients as a treated
(APaT) population. AEs (specific terms as well as system
organ class terms) were summarized by treatment arm.
Rashes that were categorized as serious AEs and anemia
were pre-specified as events of interest. The p values and
95 % CIs for between-treatment differences were
calculated using the Miettinen and Nurminen method [11].
Summary statistics for baseline, on-treatment, and change
from baseline values were provided in laboratory parame-
ters, 12-lead electrocardiogram, and vital signs.
Results
Patient disposition and baseline characteristics
This study was performed at 38 study sites in Japan
between May 2009 and February 2012. In total, 118
patients provided informed consent, of whom 90 were
randomized and completed 4 weeks of treatment with
vaniprevir/placebo plus PR and 2 weeks of follow-up
[control arm (placebo plus PR), n = 22; vaniprevir 100-mg
bid arm (vaniprevir 100 mg bid plus PR), n = 23; vani-
previr 300-mg bid arm (vaniprevir 300 mg bid plus PR),
n = 22; and vaniprevir 600-mg bid arm (vaniprevir
600 mg bid plus PR), n = 23] (Fig. 1). Seven patients were
excluded from the per protocol population due to various
reasons such as insufficient dosing of study medications.
In total, 9 patients discontinued the study after com-
pleting the post-vaniprevir 2 week follow-up period
(i.e.,[2 weeks after completing vaniprevir/placebo dosing).
Four patients withdrew consent, 2 patients were withdrawn
at the investigator’s discretion, 2 patients discontinued
because of AE(s) (1 patient in the vaniprevir 600-mg bid
arm and 1 patient in the control arm), and 1 patient in the
control arm was withdrawn because of lack of efficacy
(Fig. 1). The median (range) duration of PR therapy in each
treatment arm was as follows: vaniprevir 100-mg bid arm,
48.1 weeks (47.7, 72.1 weeks); vaniprevir 300-mg bid arm,
48.1 weeks (6.1, 72.1); vaniprevir 600-mg bid arm,
48.0 weeks (12.0, 72.0); and control arm, 49.4 weeks (29.1,
72.1). In total, 7 patients in the vaniprevir 100-mg bid arm,
5 patients in the vaniprevir 300-mg bid arm, 5 patients in the
vaniprevir 600-mg bid arm, and 10 patients in the control
arm received[48 weeks of PR therapy.
Patient characteristics were generally similar across
treatment arms (Table 1). Most patients had HCV GT1b
infection: the proportion of women was slightly higher in
the control arm and the proportion of men was slightly
higher in the vaniprevir 300-mg bid arm. Approximately
80 % of patients had previously received peginterferon
alfa-2b in combination with ribavirin.
Efficacy
Virologic response
Treatment with vaniprevir was associated with significant
improvement in virologic response compared with control
Fig. 1 Patient disposition. AE adverse event, bid twice daily, PR
peginterferon alfa-2a and ribavirin
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during the first 4 weeks of therapy. The proportion of
patients achieving RVR (the primary endpoint) was sig-
nificantly higher in each of the vaniprevir treatment arms
compared with the control arm (p\0.001 for all compari-
sons) (Fig. 2). Rates of RVR were 20 % in the control arm
compared with 86, 95, and 76 % in the vaniprevir 100-,
300-, and 600-mg bid treatment arms, respectively.
Secondary virologic endpoints also indicated profound
virologic suppression associated with vaniprevir therapy.
All patients in vaniprevir arms regardless of dose achieved
a C3-log reduction in HCV RNA from baseline by treat-
ment week 4. By comparison, of the 20 patients in control
arm, 19 (95 %) achieved a C2-log reduction in HCV RNA
from baseline at week 4 and 17 (85 %) achieved a C3-log
decline. Change from baseline in mean log HCV RNA
during the first 4 weeks of treatment was also significantly
greater in patients in vaniprevir arms than in the control
arm (Fig. 3). The model-based mean treatment differences
(vaniprevir minus control) in log HCV RNA change from
baseline at treatment week 4 were -1.8 log10 (95 % CI
-2.3, -1.2), -1.9 log10 (95 % CI -2.4, -1.3), and
-1.6 log10 (95 % CI -2.2, -1.1) in the vaniprevir 100-,
300-, and 600-mg bid arms, respectively.
The proportion of patients achieving SVR in the control,
vaniprevir 100-, 300- and 600-mg bid arms were 72, 95,
100, and 100 %, respectively (Fig. 4).


















Male 8 (36.4) 11 (47.8) 15 (68.2) 11 (47.8) 45 (50.0)
Female 14 (63.6) 12 (52.2) 7 (31.8) 12 (52.2) 45 (50.0)
HCV genotype, n (%)
GT1a 1 (4.5) 1 (4.3) 1 (4.5) 0 (0) 3 (3.3)
GT1b 21 (95.5) 22 (95.7) 21 (95.5) 23 (100) 87 (96.7)
Prior therapy
Peginterferon alfa-2a 6 (27.3) 3 (13.0) 5 (22.7) 6 (26.1) 20 (22.2)
Peginterferon alfa-2b 19 (86.4) 20 (87.0) 19 (86.4) 18 (78.3) 76 (84.4)
Age (years)
Mean ± SD 54.7 ± 6.9 55.0 ± 6.5 54.3 ± 7.6 56.3 ± 7.8 55.1 ± 7.1
Median (range) 56.5 (40, 64) 56.0 (38, 63) 56.5 (36, 63) 59.0 (36, 65) 57.0 (36, 65)
Weight (kg)
Mean ± SD 61.2 ± 12.4 63.6 ± 10.1 66.6 ± 12.5 63.6 ± 16.0 63.8 ± 12.8
Median (range) 60.2 (38.1, 91.6) 60.9 (49.0, 89.0) 66.8 (50.0, 99.5) 62.0 (42.2, 122.8) 61.6 (38.1, 122.8)
Baseline HCV RNA (log10 IU/mL)
Mean ± SD 6.6 ± 0.5 6.6 ± 0.6 6.6 ± 0.6 6.5 ± 0.9 6.6 ± 0.7
Median (range) 6.7 (5.5, 7.4) 6.7 (5.2, 7.4) 6.8 (5.0, 7.3) 6.9 (4.5, 7.7) 6.7 (4.5, 7.7)
White blood cells (102/lL)
Mean ± SD 51.2 ± 14.1 51.1 ± 13.3 54.3 ± 13.7 50.2 ± 13.1 51.7 ± 13.4
Median (range) 47.5 (27.0, 86.0) 48.0 (31.0, 77.0) 52.0 (33.0, 81.0) 49.0 (31.0, 86.0) 49.0 (27.0, 86.0)
Neutrophils (102/lL)
Mean ± SD 28.5 ± 11.2 29.4 ± 10.3 31.7 ± 10.2 28.2 ± 11.5 29.4 ± 10.7
Median (range) 25.0 (10.6, 59.3) 27.0 (17.2, 51.7) 30.2 (16.9, 54.7) 23.0 (16.7, 62.3) 25.7 (10.6, 62.3)
Hemoglobin (g/dL)
Mean ± SD 13.9 ± 1.1 14.4 ± 1.6 14.7 ± 1.3 14.0 ± 1.6 14.2 ± 1.4
Median (range) 13.5 (12.6, 16.1) 14.1 (11.7, 18.0) 14.6 (12.5, 17.3) 14.3 (11.0, 16.7) 14.1 (11.0, 18.0)
Platelets (104/lL)
Mean ± SD 17.1 ± 3.7 20.8 ± 6.5 19.6 ± 9.1 18.2 ± 4.9 19.0 ± 6.4
Median (range) 16.7 (12.2, 24.1) 18.5 (10.9, 33.4) 17.0 (13.5, 56.8) 17.0 (12.4, 36.6) 17.2 (10.9, 56.8)
bid twice daily, GT genotype, PR peginterferon alfa-2a and ribavirin, SD standard deviation
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Resistance-associated variants
Baseline sequences of NS3/4A were obtained from all but
2 patients by population-based sequencing. Virus from 2
patients was found to encode variants known to confer
reduced susceptibility to vaniprevir, including the A156T
variant (300-mg bid arm) or the D168E variant (600-mg
bid arm), respectively. Both patients achieved RVR and
SVR.
No patient in the vaniprevir arms met the criteria for
breakthrough or non-response. Only 1 patient in the control
arm met the criteria for breakthrough with a viral load
[1,000 IU/mL during the first 6 weeks of the study.
Population sequencing of the HCV NS3/4A RNA was
performed with the samples obtained from this patient at
baseline and at the virologic failure time points; however,
no resistance variant was observed at either time point
consistent with placebo plus P/R treatment.
After the peginterferon alfa-2a and ribavirin dual-ther-
apy treatment period, only 1 patient who previously
received vaniprevir experienced relapse. This patient, in the
vaniprevir 100-mg bid arm, experienced relapse 24 weeks
after completing a 48 week treatment regimen with pegin-
terferon and ribavirin (including the initial 4 week
Fig. 2 Rapid virologic
response. PR peginterferon alfa-
2a and ribavirin, RVR rapid
virologic response (undetectable
HCV RNA at treatment week
4). *p \ 0.001 versus PR
control
Fig. 3 Mean decline in HCV
RNA from baseline to week 6.
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treatment with vaniprevir). No vaniprevir-associated RAVs
were detected at treatment failure in this patient.
Pharmacokinetics
Non-compartmental analysis was performed based on
intensive bioanalytical data of vaniprevir in the PK cohort
(n = 5 in the 100-mg bid arm, n = 4 in the 300-mg bid
arm, and n = 5 in the 600-mg bid arm). As a result, van-
iprevir was rapidly eliminated from the plasma. Plasma
exposures (AUC0–12 h and Cmax) on day 1 increased non-
linearly with dose, with disproportionately greater expo-
sure seen at higher doses (Supplementary Table 1 and
Fig. 1). Plasma exposures at steady state at week 4 also
indicated non-linearity with dose, similar to day 1 obser-
vations. There was a trend towards an increase in Tmax on
day 1 with increasing dose. Median Tmax values were 1.0 h
with vaniprevir 100 mg bid, 2.5 h with 300 mg bid, and
3.0 h with 600 mg bid. This trend remained consistent with
multiple dosing, and overall Tmax values were similar on
day 1 and week 4. Elimination half-life (t) was similar on
day 1 and at week 4. Day 1 t harmonic means were
1.8–5.3 h compared to 1.6–4.1 h at week 4. Accumulation
ratios at week 4 were 2.5-fold for AUC0–12 h and 1.6–3.3
fold for Cmax with the vaniprevir 100- and 300-mg bid
doses, but no accumulation was observed in the 600-mg bid
treatment arm. Trough concentrations (C12 h) of vaniprevir
ranged from 32–305 nM in the 100-, 300-, and 600-mg bid
treatment arms (Supplementary Table 2).
After completion of the vaniprevir dosing period,
quantifiable drug levels ([1.3 nM) were detected at week 5
in 1 patient from the 600-mg bid arm, and at week 6 in 1
patient from the 300-mg bid arm. These plasma concen-
trations were extremely low, less than 1 % of the vani-
previr Cmax. In all other patients, vaniprevir plasma
concentrations at week 5 and week 6 were unquantifiable.
Safety
All patients experienced at least 1 AE during the vaniprevir
dosing period, all of which were mild to moderate severity
except for a severe AE of depressed level of consciousness
that resolved within 2 h in 1 patient in the vaniprevir
600-mg bid arm. There were no serious AEs and no patient
discontinued treatment due to an AE or serious AE during
the vaniprevir treatment period (day 1 to week 4) or the
2 week follow-up period (up to week 6). Adverse events
occurring during the first 6 weeks of therapy with an inci-
dence rate [30 % in any treatment arm are shown in
Table 2. Gastrointestinal AEs, including diarrhea and nau-
sea, were more common in patients in the vaniprevir 600-mg
bid arm than those in the control arm or lower vaniprevir
dose arms. Other AEs were consistent with the known safety
profile of peginterferon and ribavirin, and did not display a
dose-dependent relationship with vaniprevir dosing.
Rash categorized as a serious adverse event and anemia
were pre-specified AEs of interest in the protocol. The
incidence of anemia was similar in the control arm and
vaniprevir treatment arms [14 % (3/22) in control arm, 9 %
(2/23) in the vaniprevir 100-mg bid arm, 18 % (4/22) in the
vaniprevir 300-mg bid arm, and 13 % (3/23) in the vani-
previr 600-mg bid arm] and no significant difference was
observed in each vaniprevir treatment arm compared with
the control arm (p = 0.602 in the vaniprevir 100-mg bid
arm, p = 0.684 in the vaniprevir 300-mg bid arm, and
p = 0.954 in the vaniprevir 600-mg bid arm). No rashes
categorized as serious AEs were reported in the control or
vaniprevir treatment arms.
Alanine aminotransferase and aspartate aminotransfer-
ase levels declined from baseline during the first 6 weeks
of treatment with no notable difference between the control
and vaniprevir arms (Fig. 5). Early, transient bilirubin
elevations were noted in patients in the vaniprevir 600-mg
Fig. 4 Sustained virologic
response. PR peginterferon alfa-
2a and ribavirin, SVR sustained
virologic response (undetectable
HCV RNA 24 weeks after
completing last dose of
treatment)
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bid arm; however, these elevations returned to baseline
with continued therapy. Hemoglobin levels also declined
during treatment in all treatment arms, with no notable
difference between the control and vaniprevir treatment
arms (Fig. 5).
There were no clinically meaningful differences in vital
signs or in ECG parameters between treatment arms during
the vaniprevir treatment period or the 2 week safety fol-
low-up period.
After the post-vaniprevir treatment follow-up period
([2 weeks after completing vaniprevir dosing); 8 serious
AEs were reported in 6 patients. One patient in the control
arm with severe acute renal failure and severe disseminated
intravascular coagulation died from a severe bacterial
infection (this patient was also counted as discontinuing PR
due to AEs). These serious AEs were not considered
related to vaniprevir/placebo by the investigator. The
remaining 5 serious AEs reported in single patients were
cataract, hepatic steatosis, diabetes mellitus, inguinal her-
nia, and infective spondylitis: in all cases, a causal rela-
tionship to vaniprevir/placebo was excluded by the
investigator. One additional patient in the vaniprevir
600-mg bid arm discontinued PR after the post-vaniprevir
treatment follow-up period because of a non-serious AE.
Discussion
This study shows that addition of vaniprevir to peginter-
feron alfa-2a plus ribavirin in Japanese patients with HCV
GT1 infection was associated with a rapid decline in the
HCV RNA levels, and at treatment week 4 rates of RVR
were significantly increased compared with peginterferon
alfa-2a plus ribavirin alone. All AEs but 1 were of mild
or moderate severity, and generally similar to the estab-
lished safety profile of peginterferon plus ribavirin dual
therapy. An increase in gastrointestinal AEs was noted in
patients receiving vaniprevir 600 mg bid. These efficacy
and safety findings are consistent with previous observa-
tions from phase II studies of vaniprevir in non-Japanese
patients [8–10].
Manns and colleagues have reported the results of a
previous phase II study incorporating a similar study design
to that used in the present study but with a different patient
population [8]. In the study reported by Manns and col-
leagues, vaniprevir (300 or 600 mg bid, or 600 or 800 mg
qd) was dosed with peginterferon alfa-2a and ribavirin for
4 weeks followed by peginterferon alfa-2a plus ribavirin
dual therapy for an additional 44 weeks in treatment-naive,
non-Japanese patients with chronic hepatitis C [8]. RVR
was achieved by 69–83 % of patients receiving peginter-
feron alfa-2a plus ribavirin and vaniprevir compared with
5.6 % of patients receiving peginterferon alfa-2a plus
ribavirin and placebo (control arm). SVR was achieved by
61–84 % of patients in the vaniprevir arms compared with
63 % in the control arm [8]. Thus, both the study by Manns
and colleagues [8] and data from the present study indicate
that addition of vaniprevir to peginterferon plus ribavirin is
associated with a rapid decline in HCV RNA and high rates
of RVR in patients with HCV GT1 infection.




bid ? PR (n = 23)
Vaniprevir 300 mg
bid ? PR (n = 22)
Vaniprevir 600 mg
bid ? PR (n = 23)
Adverse eventsa
Any AE, n (%) 22 (100) 23 (100) 22 (100) 23 (100)
Gastrointestinal disorders
Diarrhea 3 (13.6) 3 (13.0) 3 (13.6) 9 (39.1)
Nausea 4 (18.2) 6 (26.1) 1 (4.5) 9 (39.1)
General disorders and administration site conditions
Fatigue 4 (18.2) 7 (30.4) 2 (9.1) 6 (26.1)
Pyrexia 12 (54.5) 12 (52.2) 15 (68.2) 9 (39.1)
Investigations
Hemoglobin decreased 8 (36.4) 9 (39.1) 7 (31.8) 10 (43.5)
Neutrophil count decreased 7 (31.8) 7 (30.4) 9 (40.9) 11 (47.8)
Platelet count decreased 9 (40.9) 12 (52.2) 11 (50.0) 9 (39.1)
White blood cell count decreased 10 (45.5) 15 (65.2) 15 (68.2) 15 (65.2)
Nervous system disorders
Headache 3 (13.6) 8 (34.8) 2 (9.1) 9 (39.1)
AE adverse event, bid twice daily, PR peginterferon alfa-2a and ribavirin
a Incidence [30 % in any treatment arm occurring during the first 6 weeks of therapy
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Although in the present study an analysis of SVR was
not defined in the protocol, this endpoint was assessed in an
exploratory fashion, and the data demonstrate high rates of
SVR associated with vaniprevir therapy. Careful interpre-
tation of these data is required. The total treatment duration
of peginterferon alfa-2a plus ribavirin was not identical in
all patients because the protocol allowed a maximum of
72 weeks of treatment at the discretion of the investigator.
Furthermore, SVR rates were calculated based on the per
protocol population for consistency with the primary ana-
lysis population. Despite these limitations, SVR rates in the
present study indicate that a 4 week dosing period with
vaniprevir coadministered with peginterferon alfa-2a plus
ribavirin followed by a maximum total 72 weeks of pe-
ginterferon alfa-2a plus ribavirin offers substantial benefit
to Japanese patients with HCV infection. The relatively
high SVR rate in the control arm may also be attributed to
the extended treatment duration.
Japanese treatment guidelines recommend extending
peginterferon plus ribavirin therapy from 48–72 weeks for
patients in whom HCV RNA becomes undetectable
between treatment weeks 13 and 36 [2]. Similarly, elderly
patients and those with advanced fibrosis who attain
undetectable HCV RNA between weeks 9 and 12 are also
candidates for a 72 week treatment duration. Thus, patients
with delayed virologic response are potentially faced with a
long and arduous peginterferon and ribavirin treatment
regimen with a well-described tolerability profile, includ-
ing the influenza-like symptoms of interferon-based ther-
apy and the hemolytic anemia associated with ribavirin
therapy. Addition of a targeted therapy such as vaniprevir
to peginterferon and ribavirin has the potential to sub-
stantially reduce overall treatment duration by reducing the
on-treatment time to first undetectable HCV RNA.
The main safety observations from previous vaniprevir
phase II studies that were conducted in non-Japanese
patients included an increase in mild-to-moderate gastro-
intestinal AEs, primarily nausea, vomiting, and diarrhea.
This occurred when vaniprevir was added to peginterferon
and ribavirin [8–10]. In these studies there was no signif-
icant difference in the rates of anemia and rash between the
vaniprevir and control arms [8, 9]. Safety findings from the
Fig. 5 Change from baseline laboratory observations during vaniprevir therapy: a alanine aminotransferase; b aspartate aminotransferase;
c bilirubin; d hemoglobin. bid twice daily, PR peginterferon alfa-2a and ribavirin. *Administered with peginterferon alfa-2a and ribavirin
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present study are consistent with those previous reports. In
the present study, gastrointestinal AEs, including diarrhea
and nausea, were more common in patients receiving
vaniprevir 600 mg bid than those receiving placebo or
lower vaniprevir doses. All gastrointestinal AEs were mild
or moderate in intensity and none of them resulted in dis-
continuation of study treatment during the vaniprevir
treatment or 14 day safety follow-up period; thus, vani-
previr-based triple therapy was considered generally well
tolerated.
Drug resistance is an important consideration in the use
of HCV protease inhibitors [13]. In the present study, the
high efficacy demonstrated in vaniprevir-treated patients
limits the number of cases of drug resistance provided by
this study and restricts evaluation of drug limitations due to
resistance-derived failure. Baseline variants at positions
A156 and D168 known to confer reduced susceptibility to
vaniprevir [14] were observed in 2 patients in vaniprevir
treatment arms, with both patients achieving RVR and
SVR. It is difficult to draw general conclusions from this,
however, due to the limited data set.
PK analyses indicate that, based on a twice daily dose
regimen, vaniprevir exposure increases non-linearly with
increasing dose, with disproportionately higher exposure
achieved at higher doses. Mean trough concentrations of
vaniprevir were 32, 86, and 305 nM with the 100-, 300-,
and 600-mg bid dosing regimens. These values are several
fold above the serum-adjusted in vitro vaniprevir 50 %
effective concentration (EC50) of 5.9 nM against the HCV
GT1b replicon (Data on file, Merck & Co., Inc.), sug-
gesting that viral replication will remain suppressed at
trough plasma concentrations.
In conclusion, the results from the present study indicate
that the addition of vaniprevir to peginterferon plus riba-
virin is associated with a rapid decline in HCV RNA in
Japanese patients with HCV GT1 infection, reducing the
time to undetectable HCV RNA for a substantial number of
patients. Combined with an acceptable tolerability profile,
these data support the further evaluation of vaniprevir in
Japanese patients with HCV GT1 infection. Based on the
cumulative efficacy, safety, and PK data, vaniprevir at a
dose of 300 mg bid was selected for further evaluation in
phase III clinical trials.
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